The Difference Between Palbociclib and Dalsilide

Palbociclib and Ribociclib are two commonly used CDK4/6 inhibitors for the treatment of breast cancer. Although they all belong to the same class of drugs, there are some differences in certain aspects, including indications and specific efficacy. Patients should use these drugs rationally under the guidance of their doctors.

Palbociclib and dalsilide have slightly different chemical structures, which may lead to differences in their pharmacology and efficacy. Currently, palbociclib has been approved for the treatment of locally advanced or metastatic breast cancer that is hormone receptor(HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; while dalcilib is approved for the treatment of patients with hormone receptor-positive, human epidermal growth factor receptor2-negative recurrent or metastatic breast cancer who have progressed after previous endocrine therapy. Although both palbociclib and dalcilib have shown significant efficacy in clinical trials, specific treatment results may vary based on individual differences. Therefore, when choosing which drug to use, the decision should be based on the patient's specific situation and the recommendations of the doctor.

PalbociclibThe original drug has been launched in China and has been included in medical insurance. Currently, reimbursement is only available to patients who meet the indications. The common specifications100mg*21 pills may cost more than 6,000 yuan per box, while the original drug sold overseas is more expensive. The price of 125mg*21 pills per box may be around 10,000 yuan (the price may fluctuate due to exchange rates). Palbociclib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 125mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan (the price may fluctuate due to the exchange rate).